Agilent Technologies stock has delivered a 16.2% return over the past year, yet there is a clear split in what the valuation tools are saying, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market multiples suggest the shares are pricing in a richer scenario.
The issue now is whether Agilent Technologies' current share price already reflects the intrinsic value suggested by the DCF workup, or if the gap between that and the market multiples still leaves room for further upside.
The Discounted Cash Flow (DCF) approach estimates what Agilent Technologies is worth today based on the cash it is expected to generate in the future. The model uses the latest twelve month free cash flow of about $1.1b and assumes that Agilent Technologies continues to grow its cash generation over time, rather than shrinking or remaining flat.
On these assumptions, the DCF model arrives at an estimated intrinsic value of about $177 per share. Compared with the current share price, this implies the stock trades at roughly a 21.6% discount, so the cash flow outlook appears stronger than what the market price reflects. Because Agilent’s increased investment in HALO X ray Technologies adds both growth optionality and execution risk, the gap between price and cash flow based value may partly reflect investor caution around how effectively that capital will be put to work.
Overall, the Discounted Cash Flow workup suggests Agilent Technologies stock appears undervalued relative to its projected cash generation.
Our Discounted Cash Flow (DCF) analysis suggests Agilent Technologies is undervalued by 21.6%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
The P/E ratio is a useful way to look at Agilent Technologies because earnings remain a key driver of how the market is likely to value the stock over time. Right now Agilent trades on a P/E of about 27.7x, which sits below the Life Sciences industry average of roughly 36.6x and also below a peer group average around 43.0x.
However, the tailored fair P/E for Agilent, which adjusts for factors such as its risk profile, margins and growth expectations, is estimated at about 23.6x. That is meaningfully under the current 27.7x. This suggests investors are paying a premium to what this framework points to as a more grounded earnings multiple, even though the stock does not screen as the most expensive in its industry.
Overall, Agilent Technologies stock screens as overvalued on earnings, with its current P/E multiple sitting above the level suggested by the fair ratio model.
See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St Narratives for Agilent Technologies pick up where the valuation split leaves off by explaining which paths for growth, margins and earnings would need to occur for the stock to be worth materially more or less than it is today. Each narrative links its numbers to a clear view of how Agilent Technologies' prospects and risks could evolve, giving you something concrete to revisit as fresh information appears on the Community page.
If you have a number driven view on whether Agilent Technologies' increased investment in HALO X ray Technologies delivers on its potential, share a Narrative to put your case on record and see how it stacks up as new data comes through.
Adding your perspective now gives you a clear reference point you can come back to as Agilent Technologies' results and news flow evolve.
Do you think there's more to the story for Agilent Technologies? Head over to our Community to see what others are saying!
For Agilent Technologies, the Discounted Cash Flow (DCF) work suggests the intrinsic value sits comfortably above the current share price, while the P/E based view flags the stock as overvalued relative to its tailored fair ratio. That split largely comes down to how you weigh the timing and durability of future cash flows against what the market is already paying for earnings and growth. With the broader checks landing in a mixed zone, the key question from here is whether Agilent can turn its HALO X ray Technologies investment into reliable cash generation or whether the current earnings multiple already reflects that ambition.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com